Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $207,000.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 3,000 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director owned 31,981 shares in the company, valued at approximately $2,206,689. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 4.4%

Shares of NASDAQ TEM opened at $64.66 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32. The firm’s 50-day moving average price is $55.60 and its 200-day moving average price is $52.04. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -44.90 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the business posted ($0.22) earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. On average, equities research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in TEM. California State Teachers Retirement System increased its stake in shares of Tempus AI by 6,379.2% during the second quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock valued at $404,189,000 after buying an additional 6,869,519 shares during the period. Voloridge Investment Management LLC grew its holdings in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after acquiring an additional 1,039,176 shares in the last quarter. AQR Capital Management LLC purchased a new position in Tempus AI during the 2nd quarter valued at about $54,020,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. BTIG Research increased their target price on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. HC Wainwright decreased their target price on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Finally, Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $68.93.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target, implying roughly 24% upside from the referenced $64.66 level. The firm highlighted Tempus AI’s combination of clinical and molecular data, diagnostics, software, and AI as a difficult-to-replicate healthcare-data moat. Tempus AI Got an $80 Target and 28% Upside Call
• Positive Sentiment: Cantor also argued that Tempus AI’s data business may be valued like a lower-margin vendor rather than a scalable platform, suggesting potential for valuation expansion if investors recognize the recurring and strategic value of its data and applications segments. Tempus AI’s data business is priced like a vendor, not a platform
• Positive Sentiment: Piper Sandler upgraded TEM from Neutral to Overweight and raised its price target to $76 from $56, adding another catalyst for investor optimism. Piper Sandler Upgrades Tempus AI
• Neutral Sentiment: The broader analyst consensus remains more cautious: MarketBeat lists a Hold consensus and an average target of $67.23, although 10 analysts rate the stock Buy versus five Holds and two Sells.
• Negative Sentiment: Director Nadja West sold 3,000 shares for approximately $207,000, reducing her holdings by 8.58%. However, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance as a discretionary bearish signal. Tempus AI Director Nadja West Sells 3,000 Shares

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.